Drug manufacturer Viatris will give 340B covered entities credits on requests for purchases of dozens of NDCs at higher than 340B ceiling price during the first 11 days of August, the company says in a notice on the U.S. Health Resources and Services Administration website.
HRSA posted the company’s notice on Dec. 20. Viatris said due to a problem during a system transition, “some 340B covered entities may have been unable to access 340B ceiling prices for the impacted NDCs between August 1, 2022, and August 11, 2022.”
Entities that paid more than the 340B ceiling price because 340B pricing was unavailable should submit a credit/rebill request by Jan. 31, 2023, to the distributor from which it bought the product, Viatris said. The notice includes Viatris contact information and instructions for entities unable to process a credit/rebill through their distributor.
The list of affected NDCs is about three-and-a-half pages long.
